Safety of Hyaluronan Thiomer i.o. Implant During Combined Phacoemulsification - Non Penetrating Deep Sclerectomy

NCT ID: NCT01887873

Last Updated: 2016-04-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is designed to assess the safety of Hyaluronan Thiomer i.o. implant in patients with primary open angle glaucoma undergoing a combined phacoemulsification - non penetrating deep sclerectomy procedure.

In this study, Hyaluronan Thiomer i.o. will be implanted during a combined surgery of cataract and non - penetrating deep sclerectomy in a group of 16 patients with primary open angle glaucoma and clinically significant cataract. Given that a considerable number of glaucoma patients also suffer from cataract, it is reasonable to test Hyaluronan Thiomer i.o. during a combined procedure of phacoemulsification and deep sclerectomy. This is also of importance because a combined procedure avoids the need of a second operation in this group of patients. Finally, it has been shown that combined phacoemulsification - deep sclerectomy does not induce a further risk compared to deep sclerectomy alone(open phase I study).

Safety will be assessed based on the occurrence of adverse events.

Efficacy assessments will be performed at every visit and efficacy analysis will include:

* Proportion of subjects at each study time point which will need additional IOP lowering drug therapy to achieve an IOP reduction to values \< 21 mmHg. If a subject needs more than one drug to achieve target IOP, the number of drugs needed to achieve adequate IOP reduction will be recorded.
* Proportion of subjects at each time point which will need Neodymium:YAG goniopuncture to achieve an IOP reduction to values \< 21 mmHg.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Open Angle Glaucoma Cataract

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hyaluronan Thiomer i.o. implantable device

active treatment

Group Type OTHER

Hyaluronan Thiomer i.o. implant

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hyaluronan Thiomer i.o. implant

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women aged over 18 years
* Primary open angle glaucoma with uncontrolled IOP (IOP \> 21 mmHg or more) despite maximally tolerated topical medication
* Clinically significant cataract as judged by the investigator
* Scheduled for combined cataract/glaucoma surgery

Exclusion Criteria

Any of the following will exclude a subject from the study:

* Participation in a clinical trial in the 3 weeks preceding the study
* Presence or history of a severe medical condition as judged by the clinical investigator
* Wearing of contact lenses
* Loss of mean deviation of visual field testing of 15 dB or more
* Diabetic retinopathy
* Dysgenetic glaucoma, secondary glaucoma or any type of angle closure glaucoma
* Previous argon laser trabeculoplasty
* Severe dry eye syndrome as judged by the investigator
* Ocular infection or clinically significant inflammation as judged by the investigator
* Ocular surgery in the 12 months preceding the study
* History of glaucoma surgery in the study eye
* Neovascular form of age related macular degeneration
* The following lenses will not be implanted during cataract surgery Multifocal lenses Toric lenses PMMA lenses
* Ametropy \>/= 6 Dpt
* Patients in which the surgical procedure cannot be performed or completed according to the protocol for any reason will be excluded and replaced.
* Pregnancy, planned pregnancy or lactating
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Croma-Pharma GmbH

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Ophthalmology, Medical University of Vienna, Austria

Vienna, , Austria

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OPHT150611

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.